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Abstract
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Introduction
Development of implantable cardioverter-defibrillators (ICD) has been a dramatic advancement
in the management of patients with ventricular arrhythmias. A major issue in patients with ICD
is the high incidence of ICD therapies[1-7], which have a major effect on morbidity and quality
of life [4,5]. Knowing the predictors of appropriate ICD therapy could also help to better identify
candidates for ICD therapy. This is a retrospective single centre study to identify potential
predictors of appropriate ICD therapies.
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Methods
Patients Population
Between January 2001 and January 2005, 162 patients with coronary artery disease (CAD) or
dilated cardiomyopathy (DCM) underwent ICD implantation at our centre. Among these 94
(58%) received single-chamber and 68 (42%) received dual-chamber ICD. The left ventricular
ejection fraction (EF) was measured by transthoracic echocardiography. All the patients gave
written informed consent for the procedure of ICD implantation. The mean age was 58.2 ± 13.5
years. Table 1 and and22 show the basic characteristics of the patients.
Table 1
Baseline characteristics of patients based on underlying heart disease
Open in a separate window
*: LVEF: Left ventricular ejection fraction
**: ACE: Angiotensin converting enzyme
‡CAD: Coronary heart disease
¶DCM: Dilated cardiomyopathy
†NS: non-significant
Table 2
Characteristics of patients based on ≥ 1 appropriate ICD therapy
*: The subgroups of left ventricular ejection fraction and QRS duration are chosen based on the median values in the
study population
**: Sustained ventricular arrhythmia requiring ICD therapy
‡Appropriate ICD therapy
†Patients with sustained monomorphic ventricular tachycardia requiring ICD therapy
Implanted ICDs and programming
The implanted devices were manufactured by Medtronic ([GEM-VR, GEM-DR, GEM-II-VR,
GEM-II-DR, GEM-III-VR, GEM-III-DR, Marquis-VR, Marquis-DR] Medtronic Inc.,
Minneapolis, MN, USA) and St. Jude ([Photon-VR, Photon-DR, Photon-μ-VR, Photon-μ-DR,
Atlas-VR, Atlas-DR, Epic-VR, and Epic-DR] St. Jude Medical Inc. Sylmar, CA, USA). In
implanted devices all the detection and discrimination criteria were activated with the nominal
values. In all the devices we defined ventricular fibrillation zone (300 ms) plus one VT zone
(400 ms). If the patient had an episode of spontaneous or induced sustained monomorphic VT
slower than 370 ms we extended the VT zone to VT cycle length plus 40ms. In the VT detection
zone the first therapy was three antitachycardia bursts pacing. We used the nominal values of the
ICDs for the duration and tachyarrhythmia detection criteria.
ICD Data Storage and Retrieval
After ICD implantation the patients were followed on a regular basis (3 months) and upon
receiving high voltage therapy in our outpatient ICD clinic. The devices were interrogated at
each session and the complete set of data (including intracardiac electrograms) was recorded on
floppy diskettes. The summary of the episodes were also recorded in the patient’s file. The
floppy diskettes were used in this study to retrieve all spontaneous sustained arrhythmia episodes
resulted in ICD therapy. These episodes resulted in ICD therapies, studied by two independent
electrophysiologists (AA and MRD) to define the diagnosis. In case of discrepancy in diagnosis
the final analysis of the arrhythmia episode was made by a consensus of three
electrophysiologists (AA, MRD, and MH). Beside from diagnosis, the time of arrhythmia after
implantation and the mode of therapy were recorded.
Definitions
Appropriate ICD therapy was defined as an antitachycardia pacing or shock therapy for
ventricular tachycardia or fibrillation. Indication of ICD implantation was defined as secondary
prevention (n=117) in patients who had experienced aborted sudden cardiac death, sustained
ventricular arrhythmia, or syncope (whose electrophysiologic study [using three basic drive cycle
lengths of 600, 500 and 400 with up to three premature extra-stimuli from right ventricular apex
and/or outflow tract] who showed inducible sustained hemodynamically unstable ventricular
arrhythmias). The indication of ICD implantation in all the other patients (33 patients with CAD
without history of syncope had left ventricular ejection fraction < 40%, nonsustained ventricular
tachycardia on Holter monitoring, and inducible sustained hemodynamically unstable ventricular
arrhythmia during electrophysiologic study; and 13 asymptomatic patients with DCM with
nonsustained ventricular tachycardia during Holter monitoring who had inducible sustained
hemodynamically unstable ventricular arrhythmia during electrophysiologic study) was
categorized as primary prevention [6].
Statistics
Variables are expressed as mean ± SD, and percentage. Differences in frequency of
characteristics were assessed by independent sample student’s t-test for continuous variables.
Chi-square statistics (or fisher’s exact test if applicable) used for discrete variables. We used
binary logistic regression analysis with forward selection method to find the potential predictors
of appropriate ICD therapy after device implantation. A two-tailed p-value < 0.05 was
considered statistically significant. We used SPSS® 13.0 (SPSS Inc. Chicago, IL, USA) for data
storage and analysis.
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Results
Baseline Characteristics
One hundred sixty two patients (123 men) with ICD were followed for a mean of 15±11
months. Table 1 and and22 show the baseline characteristics of these patients. We compared
patients’ characteristics between different underlying diseases (Table 1). We took into account
these differences in subsequent statistical analysis to find potential predictors of appropriate ICD
therapy. Among 49 patients who received ICD as primary prevention, 20 (41%) received
appropriate ICD therapy. Among 113 patients who received ICD as a secondary preventive
measure 34 (30%) received appropriate ICD therapy (unadjusted odds ratio [OR] = 1.74, 95%
confidence interval [CI]: 0.8 - 3.6, Mantel-Haenszel P value P=0.14). We adjusted this analysis
for left ventricular EF, QRS width, gender, and underlying heart disease which resulted in
adjusted OR = 1.66, 95% CI = 0.7 – 4.0, Mantel-Haenszel P value P=0.355. During the same
period 30.2% (n = 49) of patients received inappropriate ICD therapy. Twenty seven out of 54
patients (50%) who received appropriate ICD therapy received also inappropriate ICD therapy.
The rate of inappropriate ICD therapy among patients who did not receive appropriate ICD
therapy (n = 108) was 20.4%. Atrial fibrillation/tachycardia, sinus tachycardia, and oversensing
were the most common causes of inappropriate ICD therapy in our patients.
Predictors of ≥ 1 Appropriate ICD therapy
During the follow up period, 54 patients (33%) received appropriate ICD therapy (Table 2).
There were several differences between patients with and without ≥ 1 appropriate ICD therapy.
We used these variables as covariates to find the predictors of appropriate ICD therapy during
the follow up period. We also included all the other parameters which showed a P<0.3 during bi-
variable correlation with probability of ≥ 1 appropriate therapy a binary logistic regression
analysis model.
During binary logistic regression analysis QRS width > 100 ms (P=0.003), male sex (P = 0.021),
and DCM as underlying heart disease (P = 0.001) were correlated with ≥ 1 appropriate ICD
therapy in all patients (Table 3). We chose the subgroups of left ventricular ejection fraction and
QRS duration for this analysis based on the median values in the study population. Other factors
including age, left ventricular EF, baseline medical therapy (including amiodarone), and
indication of ICD implantation failed to correlate with the probability of ≥ 1 appropriate ICD
therapy during the follow up period (all Ps > 0.05).
Table 3
Predictors of appropriate ICD therapy
*: Odds ratio. Each odds ratio is adjusted for the other two predictor variables
**: Sustained ventricular arrhythmia requiring ICD therapy
‡Confidence interval
†Coronary artery disease
¶Dilated cardiomyopathy
Number of Appropriate ICD therapies
During our follow up period the above mentioned patients received mean number of 17±29
(range 1 – 132) appropriate ICD therapy. Among these the number of appropriate ATP was
11.9±28 (range 0 – 131) and the number of appropriate shock therapy was 5.1±9.9 (range 1 –
56). The success rate of ATP therapy among the episodes in the VT detection zone was 88%.
However, as our study is retrospective it is possible that after first appropriate ICD therapy,
electrical and/or medical treatment was adjusted or optimized to prevent new VT recurrences.
Therefore, to minimize this effect we just assessed the predictors of ≥ 1 appropriate ICD therapy
rather than total number of appropriate ICD therapies.
During subgroup analysis in patients with CAD and DCM, QRS duration > 100 ms was
correlated with the probability of ≥ 1 appropriate ICD therapy during binary logistic regression
(P = 0.006 and P = 0.003, respectively).
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Discussion
The main findings of this retrospective study are 1) QRS width might be a useful risk stratifier
(beyond ejection fraction) in patients with CAD and DCM; 2) adjunctive amiodarone therapy in
our patients failed to decrease the incidence of ≥ 1 appropriate ICD therapy; 3) indication of ICD
implantation did not influenced the probability of ≥ 1 appropriate ICD therapy during the follow
up period. Several points merit consideration. The rate of appropriate ICD therapy was different
in our patients compared to the other studies [1,4,7]. This difference can be at least partially
explained by the different patients population and the follow up period.
No empiric antiarrhythmic therapy (including amiodarone) is currently indicated in patients who
received an ICD. These patients frequently receive ICD shocks, which severely impair quality of
life. Intravenous amiodarone followed by oral dose, in patients with electrical storm results in
successful management of ventricular arrhythmias and possibly a long-term prognosis similar to
patients who do not have electrical storm [9,10]. The OPTIC (Optimal Pharmacological Therapy
in Implantable Cardioverter) study currently assesses the potential benefit of antiarrhythmic
medications in reduction of ICD therapy and electrical storm. In OPTIC the patients are
randomized to β-blocker, amiodarone plus β-blocker, or sotalol [9]. Amiodarone may have some
other potential benefits in patients with ICDs including the prevention of supraventricular
tachycardia, and so may decrease inappropriate ICD discharges; and the prevention of
nonsustained but symptomatic ventricular arrhythmias. Further studies are warranted to clarify
these issues [11].
Patients with ICD who received it for primary prevention of sudden cardiac death received
frequent appropriate ICD therapy. Among our patients the probability of ≥ 1 appropriate ICD
therapy among those who received ICD for primary and secondary prevention was comparable.
Although this may be partially explained by our restricted criteria of ICD implantation for
primary prevention (see definition) it also highlights the importance of implementing guidelines
of primary prevention of sudden cardiac death in daily clinical practice. However, it should be
mentioned that practically for the majority of the countries (especially the developing countries)
and health care providers it is simply economically impossible to follow all the indications
derived from the recent primary prevention ICD-trials in which the major risk stratifier is EF
[12]. Therefore, further risk stratification beyond EF is highly desirable and necessary [12].
Several epidemiological studies showed that QRS duration (both its absolute value and its
dynamic changes) predicts sudden and all-cause mortality [13-16]. These studies have shown
that the rate of sudden and non-sudden cardiac mortality increases sharply as QRS duration rises
above 120 ms. This effect is observed both in patients with and without bundle branch block.
Our finding also showed that QRS width ≥ 100 ms (median value in our study population) is
associated with increased incidence of appropriate ICD therapy (Table 3). However, a recent
comparison of QRS duration with microvolt T wave alternans showed a false negative rate of
narrow QRS complex (10.2%) among MADIT II like patients which could limit its value as a
risk predictorc [17].
Finally, only 57% of our patients received beta-blocker therapy. There is substantial evidence
that beta blocker therapy has positive effects on morbidity, and mortality, in patients who have
been diagnosed with heart failure and/or CAD. Beta blockers should be considered a cornerstone
of therapy for these patients [18-20]. Therefore although in our study beta-blocker therapy failed
to reduce the incidence of appropriate ICD therapy, beta-blockers should be administered to all
patients with CAD and DCM who have ICD unless an absolute contraindication is present. This
will decrease the morbidity and mortality in these patients as the beneficial effect of beta-
blockers in these patients is additive to the effect of ICD.
Study limitation
Although we showed that (1) the adjunctive amiodarone therapy do not reduce the incidence of ≥
1 appropriate ICD therapy and (2) beta-blockers failed also to reduce it, our study was
retrospective and non-randomized. Before making any conclusion from our data we have to wait
for results of randomized studies such as OPTIC.
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